Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | NQO1 | P15559 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154192 | 0.87 | AHR (0.45) | AHRTSHRSMN1; SMN2MAPTNPC1 | |
| SCHEMBL14417987 | 0.84 | NR5A1 (0.46) | AHRTSHRTP53 | |
| SCHEMBL6155704 | 0.84 | NR5A1 (0.46) | AHRTSHRTP53 | |
| SCHEMBL14831139 | 0.83 | NR5A1 (0.49) | AHRTSHRTP53 | |
| SCHEMBL6155245 | 0.83 | NR5A1 (0.49) | AHRTSHRTP53 | |
| SCHEMBL6153907 | 0.83 | NR5A1 (0.49) | AHRTSHRTP53 | |
| SCHEMBL6154475 | 0.81 | PTGS2 (0.43) | PTGS2NQO1RELAESR1AHR | |
| SCHEMBL2152818 | 0.80 | FBP1 (0.49) | PTGS2RELAESR1AHRTSHR | |
| SCHEMBL6154339 | 0.80 | LCK (0.48) | PTGS2MAOBSMN1; SMN2MAPTNPC1 | |
| SCHEMBL6153914 | 0.79 | ALDH1A1 (0.45) | TDP1SMN1; SMN2MAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | claimed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | claimed |
| CN-1281432-A | alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing them | CENTAUR PHARMACEUTICALS INC (US) | 2001-01-24 | — | — | CN | claimed |
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | KELLEHER JUDITH A (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6433008-B1 | TREATING PARKINSON*S, ALZHEIMER*S, AUTOIMMUNE AND RHEUMATIC DISEASES; HUMAN IMMUNODEFICIENCY VIRUS (HIV) DEMENTIA, AND INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| CN-1281432-A | alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing them | CENTAUR PHARMACEUTICALS INC (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6046232-A | THERAPEUTICS FOR TREATING AND/OR PREVENTING NEUROLOGICAL, AUTOIMMUNE AND INFLAMMATORY CONDITIONS IN MAMMALS AND AS ANALYTICAL REAGENTS FOR DETECTING FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | PTGS2 709/4885NQO1 4/4885RELA 603/4885 |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | PTGS2 755/4885NQO1 4/4885RELA 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.